LAZ Lazard Ltd Class A

Lord Prior to Serve as a Senior Adviser to Lazard Financial Advisory

Lazard Ltd (NYSE: LAZ) announced today that Lord David Prior, the former Under Secretary of State to the Department for Business, Energy and Industrial Strategy (BEIS) and Minister for NHS Productivity at the Department of Health, will serve as a Senior Adviser to Lazard, Financial Advisory, effective immediately.

As a Senior Adviser, Lord Prior will provide strategic counsel to Lazard and its clients, particularly in the healthcare sector.

Dale Raine, Managing Director and Head of Lazard’s European Healthcare team in London, said, “David will bring a unique perspective as a result of his vast knowledge of the healthcare industry and policy. His experience and connectivity will strengthen our ability to help clients to navigate fundamental changes in global healthcare delivery.’’

Lord Prior said, ’’Lazard has an excellent reputation for the quality of its advice and its people and is uniquely positioned to advise industry participants on how the important changes reshaping the healthcare industry will affect their businesses, customers, and patients. I look forward to working with the team.’’

As Under Secretary to the Department for Business, Energy and Industrial Strategy, Lord Prior was responsible for the UK Government’s Life Sciences Industrial Strategy. He worked with industry and government to provide recommendations that would enhance the life sciences sector and enable the UK to become a global hub for medical innovation.

Lord Prior has held a number of senior roles in the healthcare sector, most recently as Chairman to University College London Hospital, a role he will continue, as well as Chairman of the Norfolk and Norwich University Hospital and Chairman of the Care Quality Commission.

Lord Prior is a qualified Barrister and former Lazard banker, working for the firm in New York after graduating from Cambridge University.

Lazard has advised or continues to advise clients on a number of significant M&A transactions in the global healthcare sector, including advising Wilson Therapeutics on its sale to Alexion Pharmaceuticals, Servier on its acquisition of Shire Oncology, Express Scripts on its sale to Cigna, Aetna on its merger with CVS; Johnson and Johnson on its acquisition of Actelion; Sanofi on its acquisitions of Bioverativ and Ablynx; Gilead on its acquisition of Kite Pharma; and Ariad on its sale to Takeda.

About Lazard

Lazard, one of the world’s preeminent financial advisory and asset management firms, operates from 43 cities across 27 countries in North America, Europe, Asia, Australia, Central and South America. With origins dating to 1848, the firm provides advice on mergers and acquisitions, strategic matters, restructuring and capital structure, capital raising and corporate finance, as well as asset management services to corporations, partnerships, institutions, governments and individuals. For more information, please visit www.lazard.com. Follow @Lazard

EN
30/04/2018

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Lazard Ltd Class A

Lazard Inc: 2 directors

Two Directors at Lazard Inc sold/gave away 90,617 shares at between 0.000USD and 56.537USD. The significance rating of the trade was 75/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over ...

Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke

Vital Signs: Actionable charts

In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.

Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke

Vermilion Short Shots: Technically Vulnerable Stocks

Short Shots is a collection of technically vulnerable charts culled from the Negative Inflecting and Toppy columns within our Weekly Compass report or from various technical screening processes. The charts contained in this report have developed concerning technical patterns that suggest further price deterioration is likely. For these reasons Short Shots can also be a great source of ideas for investors interested in short-selling candidates.

Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke

Vital Signs: Actionable charts

In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.

ResearchPool Subscriptions

Get the most out of your insights

Get in touch